Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?

Keyphrases

• Muscle-invasive Bladder Cancer 100%
• Bladder Preservation 100%
• Patient Selection 66%
• Radical Cystectomy 66%
• Bladder-sparing 66%
• Significant Risk Factors 33%
• Randomized Controlled Trial 33%
• Surgeons 33%
• Bladder 33%
• Quality of Life 33%
• Complication Risk 33%
• Mortality Risk 33%
• Cisplatin-based Chemotherapy 33%
• Hospital Readmission 33%
• Expert Opinion 33%
• Tumor Stage 33%
• Disease-specific Survival 33%
• Medical Comorbidity 33%
• Well-being 33%
• Urologic 33%
• Combined Modality Therapy 33%
• Upper Tract Urothelial Carcinoma 33%
• Lifestyle Modification 33%
• European Guidelines 33%
• American Urological Association 33%
• National Comprehensive Cancer Network Guidelines 33%
• Muscle-invasive 33%
• Invasive Urothelial Carcinoma 33%
• Muscle-invasive Urothelial Bladder Cancer 33%
• Partial Cystectomy 33%
• PubMed Literature 33%
• Neoadjuvant Cisplatin 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Muscle Invasive Bladder Cancer 100%
• Malignant Neoplasm 33%
• Chemotherapy 33%
• Randomized Controlled Trial 33%
• Cisplatin 33%
• Disease Specific Survival 33%
• Cancer Staging 33%
• Bladder Cancer 33%
• Transitional Cell Carcinoma 33%
• Comorbidity 33%

Medicine and Dentistry

• Bladder 100%
• Muscle Invasive Bladder Cancer 100%
• Cystectomy 42%
• Malignant Neoplasm 14%
• Surgeon 14%
• Randomized Controlled Trial 14%
• Quality of Life 14%
• Cisplatin 14%
• Bladder Cancer 14%
• Cancer Staging 14%
• Disease Specific Survival 14%
• Transitional Cell Carcinoma 14%
• Lifestyle Modification 14%
• Comorbidity 14%